MoonLake Immunotherapeutics
MLTX
$17.80
-$0.20-1.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.66% | -0.10% | 46.41% | 58.13% | 62.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.47% | 31.54% | 65.69% | 98.50% | 139.58% |
| Operating Income | -47.47% | -31.54% | -65.69% | -98.50% | -139.58% |
| Income Before Tax | -70.98% | -35.41% | -95.93% | -126.73% | -190.59% |
| Income Tax Expenses | 306.54% | 504.88% | 25.00% | 20.25% | 118.57% |
| Earnings from Continuing Operations | -71.87% | -35.83% | -95.75% | -126.39% | -190.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -25.19% | 33.29% | 68.90% | 103.64% |
| Net Income | -74.51% | -36.89% | -97.03% | -127.55% | -192.14% |
| EBIT | -47.47% | -31.54% | -65.69% | -98.50% | -139.58% |
| EBITDA | -46.86% | -30.99% | -65.31% | -98.29% | -141.67% |
| EPS Basic | -54.82% | -27.02% | -95.54% | -126.06% | -189.37% |
| Normalized Basic EPS | -55.49% | -27.24% | -96.56% | -127.16% | -190.96% |
| EPS Diluted | -54.82% | -27.02% | -95.54% | -126.06% | -189.37% |
| Normalized Diluted EPS | -55.49% | -27.24% | -96.56% | -127.16% | -190.96% |
| Average Basic Shares Outstanding | 12.71% | 7.77% | 0.75% | 0.65% | 0.95% |
| Average Diluted Shares Outstanding | 12.71% | 7.77% | 0.75% | 0.65% | 0.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |